PT-141
Bremelanotide / Vyleesi
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, developed specifically to isolate the sexual function effects from the tanning properties of its parent compound. It was FDA-approved in 2019 under the brand name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides to achieve full regulatory approval. PT-141 works centrally through melanocortin-4 receptor (MC4R) activation in the hypothalamus rather than through vascular mechanisms like PDE5 inhibitors.
作用机制
Melanocortin-4 receptor (MC4R) agonist derived from Melanotan II. Acts centrally in the hypothalamus to increase sexual desire and arousal through dopaminergic pathways. Unlike PDE5 inhibitors, works on desire rather than mechanical erectile function.
研究协议
仅供研究使用,非医疗建议。
Research protocols use 1-2mg via subcutaneous injection 45 minutes before anticipated activity. Maximum frequency: once per 24 hours, no more than 8 times per month. FDA-approved dose for HSDD is 1.75mg.
研究笔记
Clinical Research Status
PT-141 received FDA approval in June 2019 as Vyleesi (bremelanotide) for HSDD in premenopausal women, administered as a 1.75mg subcutaneous auto-injector used as-needed before sexual activity. Phase 3 RECONNECT trials demonstrated statistically significant improvements in sexual desire and reduction in distress compared to placebo. Research continues into male erectile dysfunction applications, where it has shown efficacy in patients who do not respond to PDE5 inhibitors.
Key Published Findings
Clinical trials showed that PT-141 increased the number of satisfying sexual events and improved desire scores in women with HSDD over 24-week treatment periods. In male ED studies, it produced erections in men unresponsive to sildenafil, confirming its unique central mechanism of action. Functional MRI studies demonstrate that PT-141 activates brain regions associated with sexual arousal, distinguishing it mechanistically from all other sexual dysfunction treatments.
Safety Profile
The most common side effect is nausea, occurring in approximately 40% of patients and typically diminishing with repeated use. Flushing, headache, and transient hypertension are reported in 10-20% of users. The FDA label carries a warning about transient blood pressure increases and recommends against use in patients with uncontrolled hypertension or cardiovascular disease. Dosing is limited to no more than once every 24 hours and no more than 8 doses per month.
Drug Interactions & Contraindications
PT-141 may cause additive hypotension when combined with naltrexone or other opioid antagonists used for HSDD treatment. Not recommended for use with other melanocortin receptor agonists due to overlapping receptor activity. Contraindicated in uncontrolled hypertension and should be used cautiously with antihypertensive medications due to unpredictable blood pressure effects.
Comparison to Related Compounds
Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally on vascular smooth muscle, PT-141 acts centrally on sexual desire and arousal pathways in the brain. Derived from Melanotan II but engineered to minimize melanocortin-1 receptor activity (tanning) while preserving MC4R activity (sexual function). It is the only FDA-approved treatment that directly targets the neurological component of sexual desire rather than the mechanical vascular response.
Community Observations
Research dosing for males typically ranges from 500mcg to 2mg subcutaneously, administered 2-4 hours before anticipated sexual activity. Nausea management is the primary challenge, with many users reporting that starting at lower doses (250-500mcg) and titrating up reduces initial GI side effects. Effects typically onset within 1-3 hours and can persist for 6-12 hours, with some users reporting residual effects lasting up to 72 hours.
半衰期
~2-3 hours
复溶
Bacteriostatic water (BAC)
存储
冻干
Refrigerate 2-8C up to 24 months.
复溶后
Refrigerate 2-8C. Use within 30 days.
美国法律状态
又称作
常见问题
什么是 PT-141?
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, developed specifically to isolate the sexual function effects from the tanning properties of its parent compound. It was FDA-approved in 2019 under the brand name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides to achieve full regulatory approval. PT-141 works centrally through melanocortin-4 receptor (MC4R) activation in the hypothalamus rather than through vascular mechanisms like PDE5 inhibitors.
PT-141 如何起作用?
Melanocortin-4 receptor (MC4R) agonist derived from Melanotan II. Acts centrally in the hypothalamus to increase sexual desire and arousal through dopaminergic pathways. Unlike PDE5 inhibitors, works on desire rather than mechanical erectile function.
PT-141 在美国的监管状态是什么?
FDA-approved for HSDD in women (Rx only)
PT-141 的半衰期是多少?
~2-3 hours
PT-141 还有哪些名称?
Bremelanotide, Vyleesi
Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。
阅读完整免责声明